Unknown

Dataset Information

0

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.


ABSTRACT: GIFT-I is a phase 3 trial evaluating the efficacy and safety of a 12-week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for treatment of Japanese hepatitis C virus genotype 1b-infected patients. It consists of a double-blind, placebo-controlled substudy of patients without cirrhosis and an open-label substudy of patients with compensated cirrhosis. Patients without cirrhosis were randomized 2:1 to once-daily OBV/PTV/r (25 mg/150 mg/100 mg; group A) or placebo (group B). Patients with cirrhosis received open-label OBV/PTV/r (group C). The primary efficacy endpoint was the rate of sustained virological response 12 weeks posttreatment in interferon-eligible, treatment-naive patients without cirrhosis and hepatitis C virus RNA ?100,000 IU/mL in group A. A total of 321 patients without cirrhosis were randomized and dosed with double-blind study drug (106 received double-blind placebo and later received open-label OBV/PTV/r), and 42 patients with cirrhosis were enrolled and dosed with open-label OBV/PTV/r. In the primary efficacy population, the rate of sustained virological response 12 weeks posttreatment was 94.6% (106/112, 95% confidence interval 90.5-98.8). Sustained virological response 12 weeks posttreatment rates were 94.9% (204/215) in group A, 98.1% (104/106) in group B (open-label), and 90.5% (38/42) in group C. Overall, virological failure occurred in 3.0% (11/363) of patients who received OBV/PTV/r. The rate of discontinuation due to adverse events was 0%-2.4% in the three patient groups receiving OBV/PTV/r. The most frequent adverse event in patients in any group was nasopharyngitis.In this broad hepatitis C virus genotype 1b-infected Japanese patient population with or without cirrhosis, treatment with OBV/PTV/r for 12 weeks was highly effective and demonstrated a favorable safety profile.

SUBMITTER: Kumada H 

PROVIDER: S-EPMC5049673 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.

Kumada Hiromitsu H   Chayama Kazuaki K   Rodrigues Lino L   Suzuki Fumitaka F   Ikeda Kenji K   Toyoda Hidenori H   Sato Ken K   Karino Yoshiyasu Y   Matsuzaki Yasushi Y   Kioka Kiyohide K   Setze Carolyn C   Pilot-Matias Tami T   Patwardhan Meenal M   Vilchez Regis A RA   Burroughs Margaret M   Redman Rebecca R  

Hepatology (Baltimore, Md.) 20150825 4


<h4>Unlabelled</h4>GIFT-I is a phase 3 trial evaluating the efficacy and safety of a 12-week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for treatment of Japanese hepatitis C virus genotype 1b-infected patients. It consists of a double-blind, placebo-controlled substudy of patients without cirrhosis and an open-label substudy of patients with compensated cirrhosis. Patients without cirrhosis were randomized 2:1 to once-daily OBV/PTV/r (25 mg/150 mg/100 mg; group A)  ...[more]

Similar Datasets

| S-EPMC4750684 | biostudies-literature
| S-EPMC6107263 | biostudies-literature
| S-EPMC6680211 | biostudies-literature
| S-EPMC6850388 | biostudies-literature
| S-EPMC6767547 | biostudies-literature
| S-EPMC6211326 | biostudies-literature
| S-EPMC4604390 | biostudies-literature
| S-EPMC4706288 | biostudies-literature
| S-EPMC5763364 | biostudies-literature
| S-EPMC4750706 | biostudies-literature